预约演示
更新于：2025-07-15
Mivacurium Chloride
米库氯铵
更新于：2025-07-15
概要
基本信息
原研机构 |
在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-01-22), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C58H80ClN2O14 |
InChIKeyKFWHZSUNFAPZPW-FBIVYNMFSA-M |
CAS号106861-44-3 |
关联
17
项与 米库氯铵 相关的临床试验NCT06709066
Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy
ChiCTR2300075970
Effect of mivacurium on tonsillar adenoidectomy in pediatric patients
NCT06072534
Evaluation of Effectiveness of Two Different Doses of Mivacurium in Modified Rapid Sequence Intubation for Emergency Surgery ,Prospective Randomized Double Blind Study
100 项与 米库氯铵 相关的临床结果
登录后查看更多信息
100 项与 米库氯铵 相关的转化医学
登录后查看更多信息
100 项与 米库氯铵 相关的专利（医药）
登录后查看更多信息
723
项与 米库氯铵 相关的文献（医药）2025-03-12Cureus Journal of Medical Science
Pseudocholinesterase Deficiency in Ambulatory Surgery: A Case Report
Article
作者: Franzen, Matthias ; Johnson-Gray, Elizabeth ; Allareddy, Greeshma ; Pandey, Priyanka ; Shaffer, Austin J
Pseudocholinesterase (PCHE) deficiency is a rare condition that results in increased sensitivity to certain medications, including the paralytic agents succinylcholine and mivacurium. PCHE deficiency typically presents when patients cannot be weaned off the ventilator because of residual paralysis. These patients require mechanical ventilation and sedation until they are strong enough to be safely extubated. This report presents the case of a 53-year-old male patient whose only known surgical and anesthetic complication was post-op nausea and vomiting and who was diagnosed with PCHE deficiency after he could not be safely extubated in the operating room (OR) after a robotic inguinal hernia repair. The patient was admitted to the ICU and successfully extubated several hours later.
2024-10-04MEDICINE
A novel BCHE frameshift mutation in a Chinese woman with butyrylcholinesterase deficiency: A case report and literature review
Review
作者: Zeng, Jiantao ; Yang, Dan ; Zheng, Zhaobin ; Dai, Tao ; Xia, Jun
Rationale::
Congenital butyrylcholinesterase deficiency (BCHED) is a rare autosomal recessive genetic disorder caused by a pathogenic mutation in the BCHE gene. Patients with BCHED may experience prolonged apnea or even death after the application of drugs such as succinylcholine. We aimed to identify the genetic basis of disease in a patient presenting with butyrylcholinesterase deficiency in order to confirm the diagnosis, expand BCHE gene mutation spectrum, and elucidate potential genotype-phenotype associations to inform management.
Patient concerns::
A 51-year-old woman presented with “vague pain in the upper and middle abdomen.” Her serum cholinesterase level was 211 U/L (reference value 4000–13,000 U/L). Other laboratory findings were normal. Genetic analysis revealed compound heterozygous mutations in BCHE gene, which was considered pathogenic in this case.
Diagnoses::
The patient presented with low serum cholinesterase levels, which excluded common causes such as liver disease, drug toxicity, and chronic illness. Whole exon examination revealed compound heterozygous mutations in the BCHE gene; thus, the patient was diagnosed with congenital BCHED.
Interventions::
Gastroscopy without succinylcholine or mivacurium chloride was recommended. The gastroscopy results were “gastric polyps,” and gastroscopic “polypectomy” was performed. The patient was advised to avoid succinylcholine use.
Outcomes::
The patient’s serum cholinesterase level was reviewed 3 months later, and the result was 215 U/L. Double heterozygous mutations are the cause of BChE deficiency of this woman in this study, including a novel mutation NM_000055.4: c.666_669del (p.Phe223Glufs*38). A review of the literature reveals considerable variation in the hotspot variants of the BCHE gene across different populations. The Chinese population displays a higher prevalence of the silent type, which is more sensitive to anesthetics such as succinylcholine.
Lessons::
Clinical manifestations of congenital BCHED were not significant. This study avoided a potential anesthetic accident, and the novel variant enriched the BCHE gene mutation spectrum.
2024-08-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Onset time, duration of action, and intubating conditions after mivacurium in elderly and younger patients
Article
作者: Dalsten, Helene ; Rosager, Christine L. ; Wadland, Sarah Sofie ; Kempff‐Andersen, Sebastian ; Creutzburg, Andreas ; Rasmussen, Lars S. ; Rosenkrantz, Oscar ; Vested, Matias
Abstract:
Background:
The neuromuscular blocking agent mivacurium can be used during anesthesia to facilitate tracheal intubation. Data on onset time, duration of action, and effect on intubating conditions in patients 80 years and older are however limited. We hypothesized that onset time and duration of action of mivacurium would be longer in elderly patients than in younger adults.
Methods:
This prospective observational study included 35 elderly (≥80 years) and 35 younger (18–40 years) patients. Induction of anesthesia comprised fentanyl 1–3 μg kg−1 and propofol 1.5–2.5 mg kg−1 and propofol and remifentanil for maintenance. Acceleromyography was used for monitoring neuromuscular blockade. The primary outcome was onset time defined as time from injection of mivacurium 0.2 mg kg−1 to a train‐of‐four (TOF) count of zero. Other outcomes included duration of action (time to TOF ratio ≥0.9), intubating conditions using the Fuchs‐Buder scale and the intubating difficulty scale (IDS), and occurrence of hoarseness and sore throat postoperatively.
Results:
No difference was found in onset time comparing elderly with younger patients; 219 s (SD 45) versus 203 s (SD 74) (difference: 16 s (95% CI: −45 to 14), p = .30). Duration of action was significantly longer in elderly patients compared with younger patients; 52 min (SD 17) versus 30 min (SD 8) (difference: 22 min [95% CI: 15 to 28], p < .001). No difference was found in the proportion of excellent intubating conditions (Fuchs‐Buder); 31/35 (89%) versus 26/35 (74%) (p = .12) or IDS score (p = .13). A larger proportion of younger patients reported sore throat 24 h postoperatively; 34% versus 0%, p = .0002. No difference was found in hoarseness.
Conclusion:
No difference in onset time of mivacurium 0.2 mg kg−1 was found comparing elderly and younger patients. However, elderly patients had significantly longer duration of action. No difference was found in intubating conditions.
100 项与 米库氯铵 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 2005-08-11 | |
| 麻醉 | 美国 | 1992-01-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 24 | (Moderate/Normal Surgical Block) | 積鏇鏇繭醖築壓鹽選鹽(淵簾醖獵願鏇齋蓋憲網) = 糧網構鏇衊醖構鹹鹽膚 夢築憲艱獵願顧衊淵衊 (糧鏇蓋製簾糧糧構繭窪, 0.4) 更多 | - | 2016-10-17 | ||
(Deep Surgical Block) | 積鏇鏇繭醖築壓鹽選鹽(淵簾醖獵願鏇齋蓋憲網) = 遞窪願膚夢簾網鬱壓獵 夢築憲艱獵願顧衊淵衊 (糧鏇蓋製簾糧糧構繭窪, 0.4) 更多 | ||||||
N/A | - | - | Mivacurium 50 microg/kg | 憲範鹹獵遞簾衊網齋網(積遞觸窪製壓鏇壓鑰襯) = 簾網憲鹽醖網積夢餘遞 鏇顧網簾鹹糧鑰觸衊選 (鏇夢憲積齋願獵鏇獵衊, 82 ~ 127) 更多 | - | 2001-12-01 | |
Mivacurium 100 microg/kg | 憲範鹹獵遞簾衊網齋網(積遞觸窪製壓鏇壓鑰襯) = 鹹廠壓構構廠獵製淵廠 鏇顧網簾鹹糧鑰觸衊選 (鏇夢憲積齋願獵鏇獵衊, 51 ~ 82) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用